JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES
The instant invention provides a method for treating patients by administering a JAK inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is a JAK2 inhibitor. The instant invention provides a method for treating patients by administering a JAK inhibitor wherein the JAK inhibitor is selected from selected from Jak2-IA, AG490, Pyridone 6, WP1066, LS104, TG101209, TG101348, CP690,550, CP352,664, INCB18424, WHI-P154, CMP6, SB1518, XL019, CEP-701, INCB20, AUH-6-96 and AZ960.
1 . A method for treating a patient, wherein the patient will be or is currently being treated with a lipid-based nucleic acid therapeutic, by administering a JAK inhibitor.
2 . The method of claim 1 wherein the JAK inhibitor is a JAK2 inhibitor.
3 . The method of claim 1 wherein the JAK inhibitor is selected from Jak2-IA, AG490, Pyridone 6, WP1066, LS104, TG101209, TG101348, CP690,550, CP352,664, INCB18424, WHI-P154, CMP6, SB1518, XL019, CEP-701, INCB20, AUH-6-96 and AZ960.
4 . The method of claim 1 wherein the patient is pre-treated with a JAK inhibitor.
5 . The method of claim 1 wherein the patient is co-treated with a JAK inhibitor.